Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VibeX
- Development stage
- Phase 3
- Lead developer
- Glaukos
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
VibeX is a riboflavin ophthalmic solution developed by Avedro, Inc. (later acquired by Glaukos Corporation) for use in corneal collagen cross-linking (CXL) procedures. It functions as a photosensitizer, and when activated by ultraviolet A (UVA) light from a system like the KXL System, it induces cross-linking of corneal collagen fibers. This process strengthens the cornea, impeding the progression of conditions such as keratoconus and corneal ectasia, and reducing maximum corneal curvature. VibeX is applied topically to the cornea.
- Brand names
- VibeX
- Other names
- Riboflavin Ophthalmic SolutionVibeX XtraVibeX Rapid
02
Targets
COL1A2 (Type I collagen alpha-2 chain)
Beyond the preview
Go deeper on VibeX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VibeX.